Developer docs
API playgroundTry for free, no card

Search company profiles

Vyriad

Full company profile

uuid00009dd

Namestring
Vyriad
Legal namestring
Vyriad, Inc.
Websiteurl
vyriad.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Vyriad, Inc. is a privately held clinical-stage biopharmaceutical company founded in 2015 (formalized through the March 2016 merger of Omnis Pharma and Magnis Therapeutics) and headquartered in Rochester, Minnesota, where it operates a 12,000 sq. ft. GMP-certified manufacturing facility. The company develops engineered viral vectors spanning lentiviral, vesicular stomatitis virus (VSV), and measles-based platforms, with proprietary G protein engineering and a modular adaptor technology (G-Link) that retargets vectors to specific cell populations including CD3+ T cells. Its portfolio includes a lead clinical oncolytic virotherapy (Voyager-V1, VSV-IFNβ-NIS), a clinical-stage intravesical measles program (MV-NIS), a lead in vivo CAR-T candidate (VV169, BCMA-targeted, first-in-human planned for 2026), and a recently launched research-reagent line (G-Link) distributed through affiliate Imanis Life Sciences.

Vyriad serves large pharmaceutical and biotechnology companies as its primary customer segment through strategic co-development and licensing arrangements — most notably Regeneron Pharmaceuticals (since 2019) and Novartis (since November 2024) — alongside academic medical centers including Mayo Clinic (its co-founding institution) that conduct investigator-sponsored trials. Revenue is generated via upfront payments, development and commercial milestones, and tiered royalties on partnered programs, with secondary income from research-reagent sales and venture/private equity financing (cumulative capital raised exceeds $100M, anchored by an $85M Series B led by Stine Seed Farms).

The company's go-to-market combines enterprise business development targeted at pharma collaborators with strong scientific conference presence (ASH, ASGCT, AACR, ASCO, SITC) and peer-reviewed publication output. Co-founders Stephen Russell, MD/PhD, and Kah-Whye Peng, PhD, both Mayo Clinic scientists, anchor a team of over 90 researchers from 15+ nationalities with cumulative clinical experience dosing over 350 patients across 40+ sites in the USA and Brazil.

Short descriptiontext

Vyriad is a privately held, clinical-stage biopharmaceutical company developing engineered lentiviral, VSV, and measles-based viral vector platforms for in vivo CAR-T, gene therapy, and oncolytic virotherapy, partnering with large pharma (Regeneron, Novartis) and academic centers like Mayo Clinic.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRochester, United States
HQ citystring
Rochester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncolytic virotherapy, viral vector delivery, in vivo CAR-T, gene therapy platforms, cell therapy manufacturing
Industry5 codes
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Biopharmaceuticals
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Collaboration Upfront & Milestone Payments
TypeLicensing Royalties
Description

Preclinical and clinical-stage biotech generates revenue via upfront payments and development/commercial milestones from pharmaceutical partners (e.g., Novartis 2024 deal) for access to its in vivo CAR T lentiviral vector platform.

vyriad.com
2Tiered Royalties on Partnered Programs
TypeLicensing Royalties
Description

Long-term royalty stream on net sales of any partnered products that result from collaborations with pharma companies.

vyriad.com
3Reagent Sales (G-Link Research Products)
TypeHardware Sales
Description

Sale of proprietary G-Link adaptor protein for research applications via Imanis Life Sciences e-commerce storefront, enabling partner evaluation of the technology.

vyriad.com
4Venture Capital / Private Equity Financing
TypeLicensing Royalties
Description

Privately held clinical-stage biotech funded through venture and private equity investment (e.g., $85M Series B total led by Stine Seed Farms with participation from family offices).

vyriad.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
Pricing details2 tiers
1G-Link research reagent available for purchase via Imanis Life Sciences (specific price not disclosed)
ModelOtherBilling cadencePay-as-you-go
Notes

Price not publicly disclosed; available via e-commerce storefront (imanislife.com/collections/g-link/)

vyriad.com
2Employment compensation bands (e.g., Bioproduction Technologist I $52,000-$67,000; Compliance Officer $147,000-$197,000)
ModelOtherBilling cadenceAnnual
Notes

Not a product pricing; included to reflect publicly listed salary ranges for open roles

vyriad.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1G-Link
Description

A first-in-class modular adaptor protein technology (trademarked G-Link™) that binds to lentiviral vectors, masks native receptor entry, and retargets delivery to CD3+ T cells, simplifying in vivo and ex vivo CAR T workflows.

vyriad.com
Core offering1 text field

Vyriad is a clinical-stage biotechnology company that engineers targeted viral delivery platforms for in vivo gene therapy, gene editing, and oncolytic virotherapy. Its core offerings include proprietary lentiviral vector platforms with the G-Link adaptor protein for T-cell targeting, VSV-based and measles-based oncolytic virus platforms, lead clinical assets Voyager-V1 and VV169 (in vivo BCMA CAR-T), and GMP manufacturing services for clinical-grade viral therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% of humanized mice with disseminated multiple myeloma achieved complete tumor clearance within 28 days of a single IV dose of VV169 across all tested dose levels (preclinical)
+4 more records
Product overview1 text field

Vyriad is a clinical-stage biotechnology company that offers a platform-plus-modules architecture centered on engineered viral delivery systems for targeted genetic medicines. The portfolio is anchored by two core technology platforms — an Oncolytic Virus Platform comprising the VSV-based Voyager-V1 program and the Measles virus-based MV-NIS program, and an In Vivo Platforms offering that includes the proprietary lentiviral vector delivery system used for in vivo CAR-T and gene editing applications. The modular G-Link adaptor protein technology sits on top of the in vivo platform as a plug-and-play targeting layer that can be applied to both in vivo and ex vivo CAR T workflows, and the lead in vivo CAR-T candidate VV169 (BCMA-targeting multiple myeloma program) is the first clinical translation of this combined platform. Manufacturing is delivered through Vyriad's 12,000 sq. ft. GMP-compliant facility in Rochester, Minnesota.

Product and service8 records
1G-Link Proteins
CategoryPlatform technology / Modular adaptor protein
Description

First-in-class modular adaptor protein that binds to wild-type VSV-G pseudotyped lentiviral vectors, masks native LDLR receptor entry, and retargets delivery to CD3+ T cells. Its trimeric architecture (anti-LDLR domain + anti-CD3 scFv UCHT1) enables high-avidity attachment and plug-and-play use without vector redesign, applicable to both in vivo and ex vivo CAR T workflows and to Cas9-carrying engineered virus-like particles (eVLPs).

2In Vivo Platforms (Targeted Lentiviral Vector Delivery)
CategoryPlatform technology / Viral vector delivery system
Description

Vyriad's proprietary lentiviral vector delivery platforms for in vivo CAR-T and gene editing applications. Includes Platform 1 (Blinded, Retargeted VSV-G) which uses a modified VSV-G envelope to deliver transgenes to T cells, and Platform 2 (Trimeric Adapters on G-Link Proteins) which uses plug-and-play adapter caps. Delivers improved transduction efficiency, serum stability, complement resistance, and cell-specific targeting versus first-generation vectors.

3Oncolytic VSV Platform
CategoryPlatform technology / Oncolytic virus
Description

Vesicular stomatitis virus-based oncolytic virus platform administered intravenously for systemic cancer therapy. Vyriad has proprietary technology to rapidly engineer VSV to boost anticancer activity and enable noninvasive monitoring (e.g., via NIS reporter gene). Most patients lack pre-existing antiviral antibodies to VSV, making it applicable across diverse cancer indications.

4Oncolytic Measles Virus Platform (MV-NIS)
CategoryPlatform technology / Oncolytic virus
Description

Measles virus platform encoding the human thyroidal sodium iodide symporter (NIS), administered intratumorally or intravesically. Uses a fusogenic intercellular killing mechanism (formation of non-viable syncytia), with genetically programmable targeting and carrier-cell delivery to circumvent pre-existing anti-measles immunity in many patients.

5Voyager-V1 (VSV-hIFNbeta-NIS)
CategoryLead clinical asset / Oncolytic virotherapy
Description

Vyriad's lead clinical-stage VSV-based oncolytic virus, engineered with interferon beta (IFNβ) for enhanced tumor selectivity and the NIS reporter gene for noninvasive SPECT/PET imaging-based tracking. Being developed as monotherapy and in combination with immune checkpoint inhibitors (cemiplimab, pembrolizumab, avelumab). In a Phase 1 T-cell lymphoma trial, more than half of patients responded and a third achieved complete responses lasting 5-30 months.

6VV169 (BCMA-Targeting In Vivo CAR-T)
CategoryLead clinical candidate / In vivo CAR-T therapy
Description

Vyriad's lead in vivo CAR-T candidate designed as a single intravenous administration of a B-cell maturation antigen (BCMA)-targeted CAR transgene, delivered via the LV-169 lentiviral vector. Being developed in partnership with Mayo Clinic for relapsed or treatment-refractory multiple myeloma. Preclinical data showed complete OPM-2 tumor clearance in 100% of humanized mice within 28 days at all dose levels; first-in-human Phase 1 trial planned for 2026.

7MV-NIS (Bladder Cancer Program)
CategoryClinical-stage asset / Oncolytic virotherapy
Description

Vyriad's measles virus-based clinical program encoding NIS for noninvasive imaging, in Phase 1 testing as intravesical therapy in patients with urothelial carcinoma undergoing radical cystectomy but ineligible for neoadjuvant chemotherapy (NCT03171493).

8GMP Manufacturing Services
CategoryService offering / GMP-compliant manufacturing
Description

Vyriad's 12,000 sq. ft. GMP-compliant manufacturing facility in Rochester, Minnesota, with years of experience manufacturing vesicular stomatitis virus (VSV), lentiviral, and measles-based therapies. Has dosed over 200 patients with Vyriad-manufactured drugs in Phase 1 and 2 trials. Supports continuous supply and scalable production from early to late phase clinical trials.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Roger A. Lindahl, CPA (Mayo Clinic)
Strategic tierMinorTypeOthersAnnounced on2025-10-01
Description

Senior finance executive and former Chair of Mayo Clinic's Financial Reporting and Consolidations, appointed Chief Financial Officer of Vyriad; not a corporate partnership but a leadership/board connection referencing Mayo Clinic financial leadership pipeline.

vyriad.com
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-02
Description

Exclusive license agreement signed September 2, 2025 for a novel in vivo gene delivery technology developed at the Weizmann Institute by Professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin. The technology introduces a small, reversible adapter peptide that binds to a targeting protein on engineered viruses, temporarily masking native receptors while presenting a new targeting domain - preserving fusogenic function and potency while enabling high targeting specificity. Vyriad will incorporate the technology into selected development programs within its suite of viral and nanoparticle delivery systems.

Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2024-11-20
Description

Strategic collaboration announced November 20, 2024 to discover and develop in vivo CAR-T cell therapies. Combines Vyriad's active targeting lentiviral vector platform with Novartis' expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad receives upfront payment, milestone payments, and tiered royalties on each program.

Strategic tierFlagship / CoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Broad-based strategic research collaboration established in November 2019 to discover and develop new oncolytic virotherapies leveraging Vyriad's VSV platform combined with Regeneron's antibody discovery capabilities. Includes Phase 2 clinical study of Voyager-V1 (Vyriad's lead VSV-based oncolytic virotherapy) in combination with Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) across multiple cancer indications (skin, lung, liver, uterine cancers; NSCLC; melanoma). Vyriad received an upfront payment and equity investment from Regeneron. Vyriad and Regeneron are jointly designing and validating a new generation of precision targeted VSV therapies.

5Merck KGaA and Pfizer
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-07-28
Description

Collaboration announced July 28, 2018 to evaluate Vyriad's oncolytic virus Voyager-V1 in combination with avelumab (anti-PD-L1 antibody co-developed by Merck KGaA, Darmstadt, Germany and Pfizer) in a Phase 1 clinical study for metastatic colorectal cancer.

vyriad.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-04-25
Description

Partnership announced April 25, 2017 to create next generation of cancer immunotherapy treatments by combining Tessa's Virus Specific T cell (VST) platform with Vyriad's oncolytic viruses, with the goal of effectively targeting a broad range of hard-to-treat solid tumors.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2016-08-16
Description

Agreement announced August 16, 2016 for development of theranostic tests to predict responsiveness to oncolytic virotherapy. Builds on the broader Vyriad-Imanis research and commercial relationship.

8StingInn, LLC
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2016-01-01
Description

Exclusive license agreement signed for STING technology for development of enhanced oncolytic virotherapy treatments. Vyriad secured an equity position in StingInn, LLC.

vyriad.com
Strategic tierFlagship / CoreTypeStrategic or Co-development Partner
Description

Co-founding institution of Vyriad (co-founders Stephen Russell, MD, PhD and Kah-Whye Peng, PhD are Mayo Clinic scientists). Mayo Clinic is a nonprofit organization committed to clinical practice, education and research. Vyriad and Mayo Clinic have ongoing clinical research agreements to study Voyager-V1 across multiple cancer indications as monotherapy and in combination with other immunotherapies. Co-founders hold joint Mayo Clinic/Vyriad positions.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Virus engineering contract research organization based in Rochester, Minnesota. Imanis accelerates progress in regenerative medicine, provides clinical assays and research services, and collaborates closely with Vyriad on virus engineering and characterization. Imanis distributes Vyriad's G-Link research reagent (e.g., on imanislife.com/collections/g-link/). Described as an affiliate of Vyriad, Inc.

11Profectus BioSciences
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Global collaboration to develop oncolytic recombinant VSV (rVSV) vaccines for cancer immunotherapy. Announced in conjunction with Vyriad's formation from Omnis Pharma / Magnis Therapeutics merger.

vyriad.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing proprietary oncolytic virus platforms (RP1, RP2, RP3 based on HSV) for cancer treatment. Direct competitor to Vyriad in the oncolytic virotherapy space, with overlapping clinical development strategy combining oncolytic viruses with checkpoint inhibitors and similar Phase 2 development stage.

2Turnstone Biologics
TypeDirect peer
Description

Clinical-stage company developing oncolytic virus immunotherapies (lead program TIDAL-01) using a vaccinia virus platform for solid tumors. Comparable to Vyriad as an oncolytic virus developer targeting similar cancer indications and pursuing combination strategies with immunotherapy.

3Targovax
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing oncolytic virus platforms (ONCOS-102 and ONCOS-530) for solid tumor treatment. Direct peer to Vyriad's oncolytic virotherapy programs with similar Phase 1/2 development stage and combination immunotherapy approach.

TypeEmerging player
Description

Gene therapy company developing engineered AAV capsids for targeted in vivo delivery to specific tissues including CNS. Comparable to Vyriad in pursuing targeted in vivo gene delivery, though using AAV rather than lentiviral vectors - emerging player in the broader targeted gene therapy delivery category.

TypeEmerging player
Description

Clinical-stage company developing in vivo CAR-T therapies using lentiviral delivery with its VivoVec platform targeting T cells. Most direct emerging competitor to Vyriad's VV169 in vivo CAR-T approach, pursuing similar therapeutic strategy with overlapping target indications.

TypeBroad incumbent
Description

Clinical-stage gene editing company developing in vivo CRISPR/Cas9-based therapies using LNP delivery. Comparable to Vyriad as a broader in vivo genetic medicine platform company with multiple programs in clinical development and larger capitalization, representing the incumbent scale Vyriad aspires to reach.

TypeEmerging player
Description

Clinical-stage genetic medicines company developing non-viral LNP delivery systems for gene therapy and gene editing. Comparable to Vyriad in pursuing scalable in vivo genetic medicine delivery, though with non-viral rather than viral vector technology - represents an alternative platform approach to the same opportunity.

TypeBroad incumbent
Description

Clinical-stage company developing in vivo base editing therapies using LNP delivery for cardiovascular disease. Comparable to Vyriad as an in vivo genetic medicine company with clinical-stage assets, broader incumbent in the in vivo gene therapy/editing category with multiple programs advancing.

TypeDirect peer
Description

Clinical-stage cell therapy company developing Virus-Specific T cell (VST) therapies for solid tumors. Direct peer and existing collaboration partner of Vyriad - the 2017 agreement combined Tessa's VST platform with Vyriad's oncolytic viruses, making it a comparable peer in the engineered virus/cell therapy space.

TypeEmerging player
Description

Emerging in vivo cell therapy company developing targeted LNP delivery for in vivo CAR-T and gene editing applications. Direct emerging competitor to Vyriad's in vivo CAR-T approach using a different (LNP) delivery modality, with comparable early-stage positioning and similar therapeutic target opportunities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vyriad

Clinical-Stage Biopharmaceuticalsvyriad.com

Vyriad is a privately held, clinical-stage biopharmaceutical company developing engineered lentiviral, VSV, and measles-based viral vector platforms for in vivo CAR-T, gene therapy, and oncolytic virotherapy, partnering with large pharma (Regeneron, Novartis) and academic centers like Mayo Clinic.

What Vyriad does

Vyriad, Inc. is a privately held clinical-stage biopharmaceutical company founded in 2015 (formalized through the March 2016 merger of Omnis Pharma and Magnis Therapeutics) and headquartered in Rochester, Minnesota, where it operates a 12,000 sq. ft. GMP-certified manufacturing facility. The company develops engineered viral vectors spanning lentiviral, vesicular stomatitis virus (VSV), and measles-based platforms, with proprietary G protein engineering and a modular adaptor technology (G-Link) that retargets vectors to specific cell populations including CD3+ T cells. Its portfolio includes a lead clinical oncolytic virotherapy (Voyager-V1, VSV-IFNβ-NIS), a clinical-stage intravesical measles program (MV-NIS), a lead in vivo CAR-T candidate (VV169, BCMA-targeted, first-in-human planned for 2026), and a recently launched research-reagent line (G-Link) distributed through affiliate Imanis Life Sciences.

Vyriad serves large pharmaceutical and biotechnology companies as its primary customer segment through strategic co-development and licensing arrangements — most notably Regeneron Pharmaceuticals (since 2019) and Novartis (since November 2024) — alongside academic medical centers including Mayo Clinic (its co-founding institution) that conduct investigator-sponsored trials. Revenue is generated via upfront payments, development and commercial milestones, and tiered royalties on partnered programs, with secondary income from research-reagent sales and venture/private equity financing (cumulative capital raised exceeds $100M, anchored by an $85M Series B led by Stine Seed Farms).

The company's go-to-market combines enterprise business development targeted at pharma collaborators with strong scientific conference presence (ASH, ASGCT, AACR, ASCO, SITC) and peer-reviewed publication output. Co-founders Stephen Russell, MD/PhD, and Kah-Whye Peng, PhD, both Mayo Clinic scientists, anchor a team of over 90 researchers from 15+ nationalities with cumulative clinical experience dosing over 350 patients across 40+ sites in the USA and Brazil.

Vyriad firmographics

Firmographics
Name
Vyriad
Legal name
Vyriad, Inc.
Website
https://vyriad.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Vyriad is a privately held, clinical-stage biopharmaceutical company developing engineered lentiviral, VSV, and measles-based viral vector platforms for in vivo CAR-T, gene therapy, and oncolytic virotherapy, partnering with large pharma (Regeneron, Novartis) and academic centers like Mayo Clinic.
Ownership category
akta.pro rank

Vyriad industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAGAB
Gene Therapy CDMO (Viral Vector Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Oncolytic virotherapy
  • Viral vector delivery
  • In vivo CAR-T
  • Gene therapy platforms
  • Cell therapy manufacturing

Where Vyriad is headquartered

Location

Headquarters

HQ city
Rochester
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Vyriad business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. Strategic Collaboration Upfront & Milestone Payments: Preclinical and clinical-stage biotech generates revenue via upfront payments and development/commercial milestones from pharmaceutical partners (e.g., Novartis 2024 deal) for access to its in vivo CAR T lentiviral vector platform.
  2. Tiered Royalties on Partnered Programs: Long-term royalty stream on net sales of any partnered products that result from collaborations with pharma companies.
  3. Reagent Sales (G-Link Research Products): Sale of proprietary G-Link adaptor protein for research applications via Imanis Life Sciences e-commerce storefront, enabling partner evaluation of the technology.
  4. Venture Capital / Private Equity Financing: Privately held clinical-stage biotech funded through venture and private equity investment (e.g., $85M Series B total led by Stine Seed Farms with participation from family offices).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goG-Link research reagent available for purchase via Imanis Life Sciences (specific price not disclosed)
OtherAnnualEmployment compensation bands (e.g., Bioproduction Technologist I $52,000-$67,000; Compliance Officer $147,000-$197,000)

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Vyriad product offering

Product offering

Core offering

Vyriad is a clinical-stage biotechnology company that engineers targeted viral delivery platforms for in vivo gene therapy, gene editing, and oncolytic virotherapy. Its core offerings include proprietary lentiviral vector platforms with the G-Link adaptor protein for T-cell targeting, VSV-based and measles-based oncolytic virus platforms, lead clinical assets Voyager-V1 and VV169 (in vivo BCMA CAR-T), and GMP manufacturing services for clinical-grade viral therapeutics.

Product overview

Vyriad is a clinical-stage biotechnology company that offers a platform-plus-modules architecture centered on engineered viral delivery systems for targeted genetic medicines. The portfolio is anchored by two core technology platforms — an Oncolytic Virus Platform comprising the VSV-based Voyager-V1 program and the Measles virus-based MV-NIS program, and an In Vivo Platforms offering that includes the proprietary lentiviral vector delivery system used for in vivo CAR-T and gene editing applications. The modular G-Link adaptor protein technology sits on top of the in vivo platform as a plug-and-play targeting layer that can be applied to both in vivo and ex vivo CAR T workflows, and the lead in vivo CAR-T candidate VV169 (BCMA-targeting multiple myeloma program) is the first clinical translation of this combined platform. Manufacturing is delivered through Vyriad's 12,000 sq. ft. GMP-compliant facility in Rochester, Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

  • G-Link: A first-in-class modular adaptor protein technology (trademarked G-Link™) that binds to lentiviral vectors, masks native receptor entry, and retargets delivery to CD3+ T cells, simplifying in vivo and ex vivo CAR T workflows.

Products and services

  • G-Link Proteins First-in-class modular adaptor protein that binds to wild-type VSV-G pseudotyped lentiviral vectors, masks native LDLR receptor entry, and retargets delivery to CD3+ T cells. Its trimeric architecture (anti-LDLR domain + anti-CD3 scFv UCHT1) enables high-avidity attachment and plug-and-play use without vector redesign, applicable to both in vivo and ex vivo CAR T workflows and to Cas9-carrying engineered virus-like particles (eVLPs).
  • In Vivo Platforms (Targeted Lentiviral Vector Delivery) Vyriad's proprietary lentiviral vector delivery platforms for in vivo CAR-T and gene editing applications. Includes Platform 1 (Blinded, Retargeted VSV-G) which uses a modified VSV-G envelope to deliver transgenes to T cells, and Platform 2 (Trimeric Adapters on G-Link Proteins) which uses plug-and-play adapter caps. Delivers improved transduction efficiency, serum stability, complement resistance, and cell-specific targeting versus first-generation vectors.
  • Oncolytic VSV Platform Vesicular stomatitis virus-based oncolytic virus platform administered intravenously for systemic cancer therapy. Vyriad has proprietary technology to rapidly engineer VSV to boost anticancer activity and enable noninvasive monitoring (e.g., via NIS reporter gene). Most patients lack pre-existing antiviral antibodies to VSV, making it applicable across diverse cancer indications.
  • Oncolytic Measles Virus Platform (MV-NIS) Measles virus platform encoding the human thyroidal sodium iodide symporter (NIS), administered intratumorally or intravesically. Uses a fusogenic intercellular killing mechanism (formation of non-viable syncytia), with genetically programmable targeting and carrier-cell delivery to circumvent pre-existing anti-measles immunity in many patients.
  • Voyager-V1 (VSV-hIFNbeta-NIS) Vyriad's lead clinical-stage VSV-based oncolytic virus, engineered with interferon beta (IFNβ) for enhanced tumor selectivity and the NIS reporter gene for noninvasive SPECT/PET imaging-based tracking. Being developed as monotherapy and in combination with immune checkpoint inhibitors (cemiplimab, pembrolizumab, avelumab). In a Phase 1 T-cell lymphoma trial, more than half of patients responded and a third achieved complete responses lasting 5-30 months.
  • VV169 (BCMA-Targeting In Vivo CAR-T) Vyriad's lead in vivo CAR-T candidate designed as a single intravenous administration of a B-cell maturation antigen (BCMA)-targeted CAR transgene, delivered via the LV-169 lentiviral vector. Being developed in partnership with Mayo Clinic for relapsed or treatment-refractory multiple myeloma. Preclinical data showed complete OPM-2 tumor clearance in 100% of humanized mice within 28 days at all dose levels; first-in-human Phase 1 trial planned for 2026.
  • MV-NIS (Bladder Cancer Program) Vyriad's measles virus-based clinical program encoding NIS for noninvasive imaging, in Phase 1 testing as intravesical therapy in patients with urothelial carcinoma undergoing radical cystectomy but ineligible for neoadjuvant chemotherapy (NCT03171493).
  • GMP Manufacturing Services Vyriad's 12,000 sq. ft. GMP-compliant manufacturing facility in Rochester, Minnesota, with years of experience manufacturing vesicular stomatitis virus (VSV), lentiviral, and measles-based therapies. Has dosed over 200 patients with Vyriad-manufactured drugs in Phase 1 and 2 trials. Supports continuous supply and scalable production from early to late phase clinical trials.

Quantifiable outcome

  • 100% of humanized mice with disseminated multiple myeloma achieved complete tumor clearance within 28 days of a single IV dose of VV169 across all tested dose levels (preclinical)
  • +4 more outcomes

Companies that use Vyriad

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Vyriad technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Vyriad partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor, core and flagship / core.

  • Roger A. Lindahl, CPA (Mayo Clinic)minorOthers · 1 October 2025Senior finance executive and former Chair of Mayo Clinic's Financial Reporting and Consolidations, appointed Chief Financial Officer of Vyriad; not a corporate partnership but a leadership/board connection referencing Mayo Clinic financial leadership pipeline.
  • Weizmann Institute of Science (via Yeda Research and Development)coreOEM/ Whitelabel/ Licensing Partner · 2 September 2025Exclusive license agreement signed September 2, 2025 for a novel in vivo gene delivery technology developed at the Weizmann Institute by Professors Menachem Rubinstein, Gideon Schreiber, and Dr. Diana Gataulin. The technology introduces a small, reversible adapter peptide that binds to a targeting protein on engineered viruses, temporarily masking native receptors while presenting a new targeting domain - preserving fusogenic function and potency while enabling high targeting specificity. Vyriad will incorporate the technology into selected development programs within its suite of viral and nanoparticle delivery systems.
  • Novartisflagship / coreStrategic or Co-development Partner · 20 November 2024Strategic collaboration announced November 20, 2024 to discover and develop in vivo CAR-T cell therapies. Combines Vyriad's active targeting lentiviral vector platform with Novartis' expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad receives upfront payment, milestone payments, and tiered royalties on each program.
  • Regeneron Pharmaceuticalsflagship / coreStrategic or Co-development Partner · 1 November 2019Broad-based strategic research collaboration established in November 2019 to discover and develop new oncolytic virotherapies leveraging Vyriad's VSV platform combined with Regeneron's antibody discovery capabilities. Includes Phase 2 clinical study of Voyager-V1 (Vyriad's lead VSV-based oncolytic virotherapy) in combination with Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) across multiple cancer indications (skin, lung, liver, uterine cancers; NSCLC; melanoma). Vyriad received an upfront payment and equity investment from Regeneron. Vyriad and Regeneron are jointly designing and validating a new generation of precision targeted VSV therapies.
  • Merck KGaA and PfizerminorStrategic or Co-development Partner · 28 July 2018Collaboration announced July 28, 2018 to evaluate Vyriad's oncolytic virus Voyager-V1 in combination with avelumab (anti-PD-L1 antibody co-developed by Merck KGaA, Darmstadt, Germany and Pfizer) in a Phase 1 clinical study for metastatic colorectal cancer.
  • Tessa TherapeuticsminorStrategic or Co-development Partner · 25 April 2017Partnership announced April 25, 2017 to create next generation of cancer immunotherapy treatments by combining Tessa's Virus Specific T cell (VST) platform with Vyriad's oncolytic viruses, with the goal of effectively targeting a broad range of hard-to-treat solid tumors.
  • Imanis Life Sciences (Theranostics Agreement)minorStrategic or Co-development Partner · 16 August 2016Agreement announced August 16, 2016 for development of theranostic tests to predict responsiveness to oncolytic virotherapy. Builds on the broader Vyriad-Imanis research and commercial relationship.
  • StingInn, LLCminorOEM/ Whitelabel/ Licensing Partner · 1 January 2016Exclusive license agreement signed for STING technology for development of enhanced oncolytic virotherapy treatments. Vyriad secured an equity position in StingInn, LLC.
  • Mayo Clinicflagship / coreStrategic or Co-development PartnerCo-founding institution of Vyriad (co-founders Stephen Russell, MD, PhD and Kah-Whye Peng, PhD are Mayo Clinic scientists). Mayo Clinic is a nonprofit organization committed to clinical practice, education and research. Vyriad and Mayo Clinic have ongoing clinical research agreements to study Voyager-V1 across multiple cancer indications as monotherapy and in combination with other immunotherapies. Co-founders hold joint Mayo Clinic/Vyriad positions.
  • Imanis Life SciencescoreImplementation/ SI/ Consulting PartnerVirus engineering contract research organization based in Rochester, Minnesota. Imanis accelerates progress in regenerative medicine, provides clinical assays and research services, and collaborates closely with Vyriad on virus engineering and characterization. Imanis distributes Vyriad's G-Link research reagent (e.g., on imanislife.com/collections/g-link/). Described as an affiliate of Vyriad, Inc.
  • Profectus BioSciencesminorStrategic or Co-development PartnerGlobal collaboration to develop oncolytic recombinant VSV (rVSV) vaccines for cancer immunotherapy. Announced in conjunction with Vyriad's formation from Omnis Pharma / Magnis Therapeutics merger.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Vyriad competitors and assessment

Company assessment

Direct peers

  • Replimune Group: Clinical-stage biotechnology company developing proprietary oncolytic virus platforms (RP1, RP2, RP3 based on HSV) for cancer treatment. Direct competitor to Vyriad in the oncolytic virotherapy space, with overlapping clinical development strategy combining oncolytic viruses with checkpoint inhibitors and similar Phase 2 development stage.
  • Turnstone Biologics: Clinical-stage company developing oncolytic virus immunotherapies (lead program TIDAL-01) using a vaccinia virus platform for solid tumors. Comparable to Vyriad as an oncolytic virus developer targeting similar cancer indications and pursuing combination strategies with immunotherapy.
  • Targovax: Clinical-stage immuno-oncology company developing oncolytic virus platforms (ONCOS-102 and ONCOS-530) for solid tumor treatment. Direct peer to Vyriad's oncolytic virotherapy programs with similar Phase 1/2 development stage and combination immunotherapy approach.
  • Tessa Therapeutics: Clinical-stage cell therapy company developing Virus-Specific T cell (VST) therapies for solid tumors. Direct peer and existing collaboration partner of Vyriad - the 2017 agreement combined Tessa's VST platform with Vyriad's oncolytic viruses, making it a comparable peer in the engineered virus/cell therapy space.

Emerging players

  • Capsida Biotherapeutics: Gene therapy company developing engineered AAV capsids for targeted in vivo delivery to specific tissues including CNS. Comparable to Vyriad in pursuing targeted in vivo gene delivery, though using AAV rather than lentiviral vectors - emerging player in the broader targeted gene therapy delivery category.
  • Umoja Biopharma: Clinical-stage company developing in vivo CAR-T therapies using lentiviral delivery with its VivoVec platform targeting T cells. Most direct emerging competitor to Vyriad's VV169 in vivo CAR-T approach, pursuing similar therapeutic strategy with overlapping target indications.
  • Generation Bio: Clinical-stage genetic medicines company developing non-viral LNP delivery systems for gene therapy and gene editing. Comparable to Vyriad in pursuing scalable in vivo genetic medicine delivery, though with non-viral rather than viral vector technology - represents an alternative platform approach to the same opportunity.
  • Capstan Therapeutics: Emerging in vivo cell therapy company developing targeted LNP delivery for in vivo CAR-T and gene editing applications. Direct emerging competitor to Vyriad's in vivo CAR-T approach using a different (LNP) delivery modality, with comparable early-stage positioning and similar therapeutic target opportunities.

Broad incumbents

  • Intellia Therapeutics: Clinical-stage gene editing company developing in vivo CRISPR/Cas9-based therapies using LNP delivery. Comparable to Vyriad as a broader in vivo genetic medicine platform company with multiple programs in clinical development and larger capitalization, representing the incumbent scale Vyriad aspires to reach.
  • Verve Therapeutics: Clinical-stage company developing in vivo base editing therapies using LNP delivery for cardiovascular disease. Comparable to Vyriad as an in vivo genetic medicine company with clinical-stage assets, broader incumbent in the in vivo gene therapy/editing category with multiple programs advancing.

Market position

Strengths5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Vyriad social profiles

Digital presence

Vyriad compliance and trust

Trust signal

Compliance1 record

Vyriad financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vyriad leadership team

Management profile

Number of profiles

Profiles6 records

Vyriad subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vyriad funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vyriad M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vyriad

What does Vyriad do?

Vyriad is a clinical-stage biotechnology company that engineers targeted viral delivery platforms for in vivo gene therapy, gene editing, and oncolytic virotherapy. Its core offerings include proprietary lentiviral vector platforms with the G-Link adaptor protein for T-cell targeting, VSV-based and measles-based oncolytic virus platforms, lead clinical assets Voyager-V1 and VV169 (in vivo BCMA CAR-T), and GMP manufacturing services for clinical-grade viral therapeutics.

Is Vyriad a public or private company?

Vyriad is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vyriad founded?

Vyriad was founded in 2015. It employs 51 to 100 people.

Where is Vyriad based?

Vyriad is headquartered in Rochester, United States, in the North America region.

How does Vyriad make money?

Four revenue lines are on record. Strategic Collaboration Upfront & Milestone Payments are the primary driver. The others are tiered Royalties on Partnered Programs, reagent Sales (G-Link Research Products) and venture Capital / Private Equity Financing.

Who are Vyriad's main competitors?

Direct peers on record are Replimune Group, Turnstone Biologics, Targovax and Tessa Therapeutics. Emerging players are Capsida Biotherapeutics, Umoja Biopharma, Generation Bio and Capstan Therapeutics. Broad incumbents are Intellia Therapeutics and Verve Therapeutics.

Does Vyriad have an API?

No public API is recorded for Vyriad.

What industry is Vyriad in?

Vyriad's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAB, Lentiviral Vector Gene Therapy Developers, with a secondary code of HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceVyriad Begins Phase 1 Clinical Trial for Lead In Vivo CAR T Cell Therapy VV169 Following FDA Acceptance of IND ApplicationVyriad received FDA clearance to begin a Phase 1 trial of VV169, an in vivo CAR T cell therapy for relapsed/refractory multiple myeloma. The trial, open at Mayo Clinic, will enroll up to 40 patients to assess safety and efficacy. The company aims to make off-the-shelf CAR T more accessible by generating cells directly in the body.GenengnewsTargeted Lentiviral Delivery Without Vector ReengineeringVyriad's G-Link platform uses a modular protein adaptor to redirect VSV-G-pseudotyped lentiviral vectors toward T cells without genetic modification. The adaptor suppresses native tropism and targets CD3, improving CAR delivery in T cells and enabling tumor clearance in a mouse model of multiple myeloma.BioSpaceVyriad Announces Strategic Leadership Changes to Drive Next Phase of GrowthVyriad announced strategic leadership changes, promoting Luke Russell to President and appointing him to the board, while co-founder Stephen Russell transitions to Chief Scientific Officer and Executive Chairman. The restructuring aims to align executive expertise with the company's clinical-stage growth in oncology and viral delivery technologies. This move follows recent milestones including an $85 million Series B raise and planned initiation of clinical trials for its lead programs later this year.Business Wire BlogVyriad Announces Strategic Leadership Changes to Drive Next Phase of GrowthVyriad announced that Luke Russell will become president and join the board, while Stephen Russell will transition to chief scientific officer and executive chairman. The company plans to initiate clinical trials for its lead in vivo CAR T program and G-Link translation later this year.Labiotech.euEight in vivo CAR T biotechs to follow closelyEight in vivo CAR-T biotechs are profiled, including Umoja Biopharma, Vyriad, CPTx, Legend, Strand, Alaya.bio, AAVivo, and Create Medicines. Their lead candidates target CD19, BCMA, or other antigens, with some in clinical trials. Big pharma is acquiring these companies for billions.Rochester Post BulletinWith a clinical trial and 'plug-and-play' tech, Rochester's Vyriad wants to advance blood cancer careRochester-based biotechnology company Vyriad plans to begin its first human clinical trial later this year for VV169, a novel in vivo CAR-T therapy designed to treat multiple myeloma directly within the patient's body. The company recently raised $25 million to support the trial and has also debuted G-Link, a technology developed with Israel's Weizmann Institute to convert existing ex vivo CAR-T treatments into in vivo ones.dev.uaLarge drone manufacturer Vyriy is looking for IT professionals in R&D. What vacancies are open?Vyriy, a Ukrainian drone manufacturer, is recruiting IT and engineering professionals for its R&D department, listing roles such as embedded C++ developer, hardware engineer, and UAV engineer. The company's website shows 182 open vacancies, including technical positions, and the broader Ukrainian deftech job market has reached a record 3,000 openings since the start of the year.BioSpaceVyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo ApplicationsVyriad announced G-Link, a modular adaptor protein for T-cell-targeted lentiviral vector delivery, at ASGCT 2026. Preclinical data showed complete tumor clearance in a multiple myeloma model and functional CAR T cells. The platform is expected to advance toward clinical translation.AijournVyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo ApplicationsVyriad announced the launch of G-Link, a modular adaptor protein technology designed to improve T-cell-targeting delivery for in vivo and ex vivo CAR T workflows. Data demonstrated G-Link's ability to enhance precision and scalability of lentiviral vectors without adding operational complexity, showing promising results in preclinical models.Business Wire BlogVyriad Launches G-Link: A Modular Platform Advancing T-Cell Targeted Lentiviral Vector Delivery for In Vivo and Ex Vivo ApplicationsVyriad launched G-Link, a modular adaptor protein technology designed to enable targeted T-cell delivery for both in vivo and ex vivo CAR T workflows. Preclinical data presented at the ASGCT Annual Meeting demonstrated that this platform improves precision and scalability without requiring complex vector reengineering. The company also announced that its lead in vivo CAR T candidate, VV169, is expected to enter clinical development later this year.